A Clinical Study of MIL62 in Systemic Lupus Erythematosus
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ãpharmacodynamics(PD) and
ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.